Abstract
Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Current Pharmaceutical Design
Title: Current Clinical Applications of Botulinum Toxin
Volume: 15 Issue: 31
Author(s): Daniel D. Truong, Andrea Stenner and Gerhard Reichel
Affiliation:
Abstract: Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Export Options
About this article
Cite this article as:
Truong D. Daniel, Stenner Andrea and Reichel Gerhard, Current Clinical Applications of Botulinum Toxin, Current Pharmaceutical Design 2009; 15 (31) . https://dx.doi.org/10.2174/138161209789271843
DOI https://dx.doi.org/10.2174/138161209789271843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Modified and Mutant Porins in the Study on Molecular Basis of Non- Specific Diffusion
Current Protein & Peptide Science Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design The Influence of Natural Substrates and Inhibitors on the Nucleotide- Dependent Excision Activity of HIV-1 Reverse Transcriptase in the Infected Cell
Current Pharmaceutical Design Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Chaperonin GroEL: Structure and Reaction Cycle
Current Protein & Peptide Science Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice
CNS & Neurological Disorders - Drug Targets Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction
CNS & Neurological Disorders - Drug Targets Acute Methamphetamine and Benzylpiperazine Decrease Aggression- Related Behavior in Late Adolescent Male Rats
Current Psychopharmacology What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Evolutionary Divergence of Plasmodium falciparum: Sequences, Protein- Protein Interactions, Pathways and Processes
Infectious Disorders - Drug Targets The Response of the Aged Brain to Stroke: Too Much, Too Soon?
Current Neurovascular Research Long Term Ketamine and Ketamine Plus Alcohol Toxicity - What can we Learn from Animal Models?
Mini-Reviews in Medicinal Chemistry Osteoblastic Responses to LPS, Glucose-oxidised LDL and Minocycline: Therapeutic Targets for Periodontal and Cardiometabolic Diseases
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oleanolic Acid Ameliorates Aβ25-35 Injection-induced Memory Deficit in Alzheimer’s Disease Model Rats by Maintaining Synaptic Plasticity
CNS & Neurological Disorders - Drug Targets Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer
Current Cancer Drug Targets Recent Advances on Masticatory Robot
Recent Patents on Mechanical Engineering HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Mathematical Modeling of the Cancer Cell ’ s Control Circuitry: Paving the Way to Individualized Therapeutic Strategies
Current Signal Transduction Therapy